For nausea, a gentle non-dairy protein powder and small, frequent meals are helpful
and research support from Biogen, MSD, Takeda, and Pfizer
Tirzepatide (Zepbound), a dual GLP-1/GIP receptor agonist, is also approved for weight management, though evidence in post-bariatric populations is still emerging
If you are switching from another GLP-1 drug rather than restarting retatrutide, see Switching to Retatrutide
The link between the medications and cancer risk could be due to weight loss, since having overweight or obesity is linked to a higher cancer rate, or it could be from the impact GLP-1s have on certain pathways in the body
In March 2024 the FDA approved semaglutide to help to lower the risk of cardiovascular death, heart attack and stroke in overweight or obese patients (Patchen)